Recent Advances in T-Cell Lymphoma: A Conversation with Dr. Steven Horwitz

·

In this podcast, Dr. Steven Horwitz of  Memorial Sloan Kettering Cancer Center discusses recent progress in the treatment and management of T-cell lymphoma. Listen now to hear more!

Continue reading

FDA Issues Survival Alert for Melphalan Flufenamide in Multiple Myeloma Treatment

The FDA has issued an alert that melphalan flufenamide (Pepaxto®, Oncopeptides AB) in combination with dexamethasone has demonstrated an increased risk of death in the OCEAN trial (NCT03151811) of patients with multiple myeloma. Melphalan flufenamide plus dexamethasone was granted accelerated approval in February 2021 for patients with relapsed/refractory multiple myeloma who have been treated with at least four prior lines of therapy and whose disease is refractory to at least one proteasome in...
Continue reading

Antifungal Prophylaxis for Hematologic Malignancies: Yuan Wan, MD, PhD

While antifungal prophylaxis can effectively prevent invasive fungal infections in patients with hematologic diseases, there is no consensus on which prophylactic agents provide the greatest benefit for different patient populations. In a meta-analysis recently published in JAMA Network Open, a team of researchers found that among antifungal prophylactic agents, posaconazole may be the best option for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), while voriconazo...
Continue reading

Antifungal Prophylaxis for Hematologic Malignancies: Which Agent Is Best?

In a meta-analysis evaluating the efficacy of prophylactic agents against invasive fungal infections (IFIs) for patients with hematological diseases, investigators found that posaconazole may be the best option for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS), although voriconazole may be the best option for patients undergoing hematopoietic stem cell transplantation (HSCT). "Invasive fungal infections have emerged as important causes of morbidity and mortality i...
Continue reading

How Cancer Type Affects COVID-19 Outcomes: Lennard Lee, DPhil, MRCP, BMBCh

While patients with cancer are at an increased risk of experiencing poor outcomes from COVID-19, there is significant variability in COVID-19 risk and mortality among patients with different tumor types and demographics such as age and sex, with those with hematologic malignancies facing the highest risk. In this interview with i3 Health, Lennard Lee, DPhil, MRCP, BMBCh, an Honorary Research Fellow at the University of Birmingham's Institute of Cancer and Genomic Sciences, discusses the signific...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.